Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening-Reference-Cited by-同舟云学术

Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening

Published:2005 Issue:2 Volume:103 Page:242-250
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ito Kazuto,Raaijmakers René,Roobol Monique,Wildhagen Mark,Yamanaka Hidetoshi,Schröder Fritz H.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference9 articles.

1. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men

2. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region)

3. Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer

4. Second stanford conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2, 1994

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of PSA variability with prostate cancer development using large-scale medical information data: a retrospective cohort study;Genes and Environment;2023-10-17

2. A big data-based prediction model for prostate cancer incidence in Japanese men;Scientific Reports;2023-04-21

3. L ong‐term longitudinal changes in baseline PSA distribution and estimated prevalence of prostate cancer in male Japanese participants of population‐based PSA screening;International Journal of Cancer;2018-05-14

4. Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL;International Journal of Urology;2017-05-31

5. Optimal screening interval for men with low baseline prostate-specific antigen levels (≤1.0 ng/mL) in a prostate cancer screening program;World Journal of Urology;2016-07-15